Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 13, 2002

View Archived Issues

Posaconazole effective against Aspergillus fumigatus in vitro and in vivo

Antiproliferative effects of selenomethionine in human prostate cancer cells

MT-100 well tolerated over one-year period

GenOdyssee's interferon variants show preclinical potential in hepatitis C and cancer

Pro-Pharmaceuticals to advance Davanat-1 into clinic in fourth quarter

Diacrin and Terumo sign muscle cell transplantation technology agreement for Japan

Cubist and Gilead's European commercialization agreement for Cidecin terminated

Cytotoxicity of CHS-828 enhanced in PARP-1-deficient mouse fibroblasts

Melacine rights return to Corixa

Herbal complex safe and effective for the treatment of IBS

Cardioprotective effect and mechanisms of Bay-11-7085 explored

PARS (PARP) activation implicated in autoimmune islet beta-cell destruction in NOD mice

Ezetimibe + statin effective and safe in hypercholesterolemic patients with type 2 diabetes

Potent, well-tolerated PDE4 inhibitor with suitable PK profile selected for development at Merck

Selective inverse agonist at GABA-A alpha5 receptor subtype enhances cognition in rats

Milnacipran phase II trial in FMS completes enrollment ahead of schedule

Avastin fails to meet primary endpoint in phase III metastatic breast cancer trial

Considerable progress reported by Xenova in first six months of 2002

Novel antibacterial carbapenems prepared and tested at Banyu

New FTase inhibitors for cancer and other conditions claimed by Servier

Wyeth and ArQule present novel inhibitors of Abeta production

New NPY receptor modulators and their use in obesity, diabetes, etc.

Antiprotozoal and antiretroviral compounds identified by French researchers

Akzo Nobel designs new GABA-A modulators for use as sedatives, analgesics

Novel agents for stimulating melanocyte proliferation covered by BTG patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...